TY - JOUR
T1 - Beneficial effects of metoprolol in heart failure associated with coronary artery disease
T2 - A randomized trial
AU - Fisher, Michael L.
AU - Gottlieb, Stephen S.
AU - Plotnick, Gary D.
AU - Greenberg, Nancy L.
AU - Patten, Richard D.
AU - Bennett, Susan K.
AU - Hamilton, Bruce P.
N1 - Funding Information:
From the Division of Cardiology, Department of Medicine, University of Maryland School of Medicine, University of Maryland Heart Center, Department of veterans Affairs Medical Center, Baltimore, Maryland . This study was supported by research funds from the Division of Cardiology, University of Maryland and by the Research Service. Baltimore Department of veterans Affairs Medical Center, Baltimore, Maryland. It was presented in part at the 64th Annual Scientific Sessions of the American Heart Association, Anaheim, California, November 1991 and at the 42nd Annual Scientific Session of the American College of Cardiology, Anaheim, California, March 1993 .
PY - 1994/3/15
Y1 - 1994/3/15
N2 - Objectives. This clinical trial was performed to determine the safety and clinical impact of titrated metoprolol therapy in patients with heart failure, documented coronary artery disease and a low ejection fraction. Background. Despite known cardiodepressant effects, long-term use of beta-adrenergic antagonists appears to be beneficial in patients with idiopathic dilated cardiomyopathy. However, this therapy has not been critically evaluated in patients with heart failure and coronary artery disease. Methods. In 50 patients with heart failure, known coronary artery disease and an ejection fraction ≤0.40, we examined the impact of metoprolol therapy in a 6-month double-blind, placebo-controlled randomized trial, assessing the frequency of heart failure exacerbations and changes in symptoms (New York Heart Association functional class), ejection fraction and exercise duration. Placebo-treated patients who completed 6-month follow-up studies then underwent a trial with metoprolol therapy (crossover group). Results. Metoprolol was titrated to a mean maximal dose of 87 mg/day (range 25 to 100) without serious adverse reactions. During double-blind therapy, use of a beta-blocker was associated with a significant reduction in the number of hospital admissions (4% vs. 32%, p < 0.05), overall improved functional class (p = 0.02), increased ejection fraction (4 ± 7% [mean ± SD] compared with 0 ± 6%, p < 0.05) and a greater increase in exercise duration (193 ± 276 vs. 38 ± 213 s with placebo, p < 0.01). Crossover outcome paralleled the favorable impact seen during randomized metoprolol therapy. Conclusions. Cautious use of titrated metoprolol appears to be safe and beneficial when added to standard heart failure therapy in patients with dilated cardiomyopathy associated with coronary artery disease.
AB - Objectives. This clinical trial was performed to determine the safety and clinical impact of titrated metoprolol therapy in patients with heart failure, documented coronary artery disease and a low ejection fraction. Background. Despite known cardiodepressant effects, long-term use of beta-adrenergic antagonists appears to be beneficial in patients with idiopathic dilated cardiomyopathy. However, this therapy has not been critically evaluated in patients with heart failure and coronary artery disease. Methods. In 50 patients with heart failure, known coronary artery disease and an ejection fraction ≤0.40, we examined the impact of metoprolol therapy in a 6-month double-blind, placebo-controlled randomized trial, assessing the frequency of heart failure exacerbations and changes in symptoms (New York Heart Association functional class), ejection fraction and exercise duration. Placebo-treated patients who completed 6-month follow-up studies then underwent a trial with metoprolol therapy (crossover group). Results. Metoprolol was titrated to a mean maximal dose of 87 mg/day (range 25 to 100) without serious adverse reactions. During double-blind therapy, use of a beta-blocker was associated with a significant reduction in the number of hospital admissions (4% vs. 32%, p < 0.05), overall improved functional class (p = 0.02), increased ejection fraction (4 ± 7% [mean ± SD] compared with 0 ± 6%, p < 0.05) and a greater increase in exercise duration (193 ± 276 vs. 38 ± 213 s with placebo, p < 0.01). Crossover outcome paralleled the favorable impact seen during randomized metoprolol therapy. Conclusions. Cautious use of titrated metoprolol appears to be safe and beneficial when added to standard heart failure therapy in patients with dilated cardiomyopathy associated with coronary artery disease.
UR - http://www.scopus.com/inward/record.url?scp=0028195009&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028195009&partnerID=8YFLogxK
U2 - 10.1016/0735-1097(94)90641-6
DO - 10.1016/0735-1097(94)90641-6
M3 - Article
C2 - 8106700
AN - SCOPUS:0028195009
SN - 0735-1097
VL - 23
SP - 943
EP - 950
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 4
ER -